AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04345224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rigid tape
Description: The rigid tape will be applied in a standing position. The first tape will be applied from the greater trochanter to the anterior iliac crest. The second from the greater trochanter to the posterior iliac crest. Both tapes are applied with the muscle mass lifted towards the iliac crest.
Study NCT04345224 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham tape
Description: The control group (sham tape application) will receive a single strip of a Kinesio tape across the lateral affected hip without tension in the tape or muscle stretch.
Study NCT04381715 — intervention group
Intervention type: GENETIC
Intervention: Epigenetic signatures
Description: Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
Study NCT01244659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus from EMS
Description: Tacrolimus initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.
Study NCT01244659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Prograf initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.
Study NCT00989885 — intervention group
Intervention type: OTHER
Intervention: Questionnaire and polysomnography
Description: Comparison of polysomnography data records and previously made questionnaire, with the Epworth Sleepiness Scale.
Study NCT03675906 — intervention group
Intervention type: OTHER
Intervention: hypoalbuminemia
Description: hypoalbuminemia and acute kidney injury
Study NCT00968162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Conduct a pilot trial using a transplant protocol, in which the standard busulfan, cyclophosphamide and anti-thymocyte globulin conditioning regimen is modified by adding fludarabine, a highly immunosuppressive agent, in order to determine the feasibility of reducing the total dose of cyclophosphamide from its present standard of 200 mg/kg to 90 mg/kg and of busulfan from its present standard of 12.8 mg/kg (IV) to 6.4 mg/kg, using a four step dose de-escalation schema.
Study NCT01829347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ELAD
Description: ELAD is an extracorporeal system that draws blood from the subject via a dual-lumen catheter placed in a large vein, and then separates the plasma fluid (ultrafiltrate) from cellular components using a specifically-designed ultrafiltrate generator cartridge. While the cellular components are returned to the subject via the venous access, the ultrafiltrate is circulated at a high flow rate through the four metabolically-active ELAD cartridges which contain cloned, immortalized human hepatoblastoma cells (VTL C3A cells) derived from a subclone of the human hepatoblastoma cell line HepG2.
Study NCT00947180 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Electromyographic (EMG) activity was recorded from sensors placed in the anal canal, averaged, and displayed to patients to help them learn to relax the pelvic floor muscles during straining.
Study NCT01829347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care treatment
Description: Standard of care treatment is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.
Study NCT03099278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe 20 mg oral daily
Study NCT00947180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrogalvanic stimulation
Description: Electrical stimulation was applied to pelvic floor muscles through an anal plug. Frequency was 80 pulses per sec, and voltage was slowly increased from 0 to 150-350 volts as tolerated.
Study NCT00947180 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital massage
Description: Using a gloved finger, the therapist pressed on the levator ani as firmly as tolerated and moved the finger from side to side 3-4 times.
Study NCT02813694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lefamulin
Description: antibacterial agent
Study NCT01766258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-101 65mg Carbidopa
Study NCT01829347 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care treatment
Description: Standard of care treatment is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.
Study NCT04298385 — intervention group
Intervention type: OTHER
Intervention: Traction orthosis
Description: Traction applied to a finger using elastic thread and sports tape and attached to an orthosis
Study NCT02136381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LEAP intervention
Description: LEAP has 5 modules of tools and resources. LEAP is personalised based on information provided at different stages. The user determines the modules to complete (skipping or revisiting modules). Users can choose among 8 animated mentors (4 female; 4 male) to guide them through the intervention.~Users will provide demographic data, health-related information, and current lifestyles in order to tailor the advice to be received.~Advice will focus on adopting elements of a Mediterranean dietary pattern, increase physical activity, and improve social connectedness.~Participants will receive 1) Mediterranean diet recipes; 2) a step counter to monitor physical activity goals; 3) advice in how to enhance social engagement and facilitate social roles
Study NCT02136381 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Thirty participants will be randomised to a minimal intervention comparator condition, where participants will be emailed a direct link to the National Health Service (NHS) choices 'LiveWell' website (http://www.nhs.uk/LiveWell/Pages/Livewellhub.aspx).~The email will encourage the participants to access the health resources and information on the pages labelled men's health 40-60, men's health 60-plus, women's health 40-60, women's health 60-plus, as appropriate.~Participants in the control group will be assessment after two months.
Study NCT01482832 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal therapy-based treatment
Description: Interpersonal therapy-based treatment Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. (5 weekly sessions with a booster session postpartum)
Study NCT01766258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-101 105mg Carbidopa
Study NCT01766258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stalevo
Study NCT01482832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal therapy-based treatment
Description: Interpersonal therapy-based treatment Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. (5 weekly sessions with a booster session postpartum)
Study NCT03005899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB P-1501
Description: After extubation and adequate titration by Fentanyl intravenous injection, the investigational product is applied to outer upper arm or chest on patient who confirmed treatment eligibility. Fentanyl 40 μg per dose is delivered over a 10-minute period by pressing the dosing button by the subject as needed. The 10-minute dosing period is a system lock-out time, allowing for a maximum of 6 doses per hour. One system is operable for 24 hours or until 80 doses are delivered, whichever occurs first.~Duration of application of the investigational product is 24 hours. Duration of application may be extended for up to 72 hours or until the third system is used, whichever occurs first, if the patient requests it and the specified tests can be performed
Study NCT03456323 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative Care Consultation
Description: The palliative care consultation team will be led by one of the board-certified palliative care physicians at Columbia University Medical Center. Over one or more visits, the palliative care consultation team will first review intervention participants' medical records and baseline Edmonton Symptom Assessment System (ESAS) scores. They will also directly assess participants' physical and psychological symptoms. They will provide supportive counseling, make treatment recommendations for burdensome symptoms to the primary team of physicians, and will address goals of care. They will document these activities in structured electronic medical record consultation notes.
Study NCT03456323 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Patient-surrogate pairs randomized to usual care will not have a palliative care consultation intervention offered, and will receive care by their primary physicians. However, if a palliative care consultation is requested after randomization to usual care by the primary team of physicians and/or the patient/surrogate, it will be provided.
Study NCT02924155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJP002
Description: 1. Period 1 (single dose)~   * Day1: Placebo, Topical administered one drop to each eye (Once a day)~  * Day2: SJP002, Topical administered one drops to each eye (Once a day)~  * Day3: SJP002, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])~2. Period 2 (multiple dose) - Day10\~Day23: SJP002, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])
Study NCT02924155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. Period 1 (single dose)~   * Day1: Placebo, Topical administered one drop to each eye (Once a day)~  * Day2: Placebo, Topical administered one drops to each eye (Once a day)~  * Day3 Placebo, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])~2. Period 2 (multiple dose) - Day10\~Day23: Placebo, Topical administered one drops to each eye (Administered 4 times a day \[0h, 4h, 8h, 12h\])
Study NCT04649424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CanSwab
Description: New nasopharyngeal swab design.
Study NCT03005899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SyB P-1501 placebo
Description: Identical to SyB P-1501 containing hydrogel that contains the active ingredient fentanyl HCI in its structure and appearance but production of an electric current and subsequent drug administration by iontophoresis are prevented because of its modified circuit.
Study NCT04173494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Momelotinib tablets will be self-administered orally once daily
Study NCT04173494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match danazol
Description: Danazol placebo capsules will be self-administered orally twice daily
Study NCT04173494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danazol
Description: Danazol capsules will be self-administered orally twice daily
Study NCT04173494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match momelotinib
Description: Momelotinib placebo tablets will be self-administered orally once daily
Study NCT01599988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caseinate
Description: The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Caseinate
Study NCT01599988 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk Protein Isolate
Description: The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Milk Protein Isolate.
Study NCT03448913 — intervention group
Intervention type: PROCEDURE
Intervention: PECS block
Description: It consists in injection of 20-30 ml of local anesthetic between pectoral minor, pectoral major, and serratus muscles.
Study NCT03403049 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon Ion
Description: Study subjects will receive carbon ion radiotherapy (CIRT), with daily fraction sizes of 3 GyE. The total CIRT dose will increase with each dose level. Subjects in dose level 1 and 2 will receive photon radiotherapy as well.
Study NCT03403049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Cisplatin
Description: Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy.
Study NCT03403049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Capecitabine
Description: Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy.
Study NCT03403049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine + Erlotinib
Description: Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy.
Study NCT03403049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy.
Study NCT03403049 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon
Description: During this study, the prescribed dose shall be administered according to the dose escalation shown in the table, starting with dose level 1. The carbon ion dose shall be gradually escalated while gradually reducing the dose of photons until eventually administering a full dose of 56 GyE/14 Fx carbon ions (fractional dose of 4 GyE). Dose escalation will be performed in parallel for two patient groups: patients whose pancreatic tumors are greater than 5 mm from the duodenum (Group A) and those whose tumors are within 5 mm of the duodenum (Group B). Enrolled patients will be monitored for 90 days after radiotherapy starts for any acute toxic reaction and to explore the maximum tolerated dose, in addition to being observed for any related long-term toxic reactions in accordance with the protocol.
Study NCT01608594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of ipilimumab10mg/kg
Description: Ipilimumab IV infusion:~* Day 0 (within 1-2 weeks of baseline biopsy) every 3 weeks for 2 doses followed by definitive surgery~* After surgery recover-y resume at the same dose for 2 additional doses given 3 weeks apart~* Dose continued 12 weeks later for 4 additional doses given 12 weeks apart~Interferon Alfa-2b will be given concurrently with ipilimumab. Each patient will receive Interferon Alfa-2b at 20 MU/m²/day intravenously for 5 consecutive days out of 7 every week for 4 weeks, followed by 10 MU/m²/d subcutaneously every other day, 3 times each week for 2 weeks, followed by definitive surgery. After surgery recovery, Interferon Alfa-2b will be resumed at 10 MU/m²/d subcutaneously, every other day three times a week for 46 additional weeks.
Study NCT01608594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of ipilimumab 3mg/kg + HDI
Description: Ipilimumab IV infusion:~* Day 0 (within 1-2 weeks of baseline biopsy) every 3 weeks for 2 doses followed by definitive surgery~* After surgery recover-y resume at the same dose for 2 additional doses given 3 weeks apart~* Dose continued 12 weeks later for 4 additional doses given 12 weeks apart~Interferon Alfa-2b will be given concurrently with ipilimumab. Each patient will receive Interferon Alfa-2b at 20 MU/m²/day intravenously for 5 consecutive days out of 7 every week for 4 weeks, followed by 10 MU/m²/d subcutaneously every other day, 3 times each week for 2 weeks, followed by definitive surgery. After surgery recovery, Interferon Alfa-2b will be resumed at 10 MU/m²/d subcutaneously, every other day three times a week for 46 additional weeks.
Study NCT01416038 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: Vaccine targeting survivin antigen will be administered subcutaneously.
Study NCT01416038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose cyclophosphamide (oral)
Description: Low dose cyclophosphamide will be taken by mouth.
Study NCT03104413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for risankizumab IV
Description: placebo for risankizumab administered as intravenous (IV) infusion.
Study NCT03104413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab SC
Description: risankizumab administered by subcutaneous (SC) injection
Study NCT02952443 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exercise
Description: Participants will be randomized, using a table of random numbers, to either an Exercise (EX) or a Control (CON) group. The EX group will participate in a 16-week multi-component training intervention (3x per week, 45 to 60 minutes/session, at moderate to vigorous intensity) that will include primarily resistance exercises, an aerobic warm-up and cool down, and include both flexibility and balance exercises throughout the session (Bray et al., 2016).
Study NCT02952443 — intervention group
Intervention type: BEHAVIORAL
Intervention: Control
Description: The CON group will be asked to maintain their normal daily living habits for the same duration (16 weeks). At the conclusion of the 16-weeks the exercise program will be made available to the CON group.
Study NCT01790997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1033
Description: 1 tablet of DLBS1033 490 mg thrice daily, after meal
Study NCT01790997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 1 tablet of aspirin 80 mg once daily, after meal
Study NCT01790997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 1 tablet of clopidogrel 75 mg once daily, after meal
Study NCT04090801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical minoxidil 5% in 90% ethanol and 5% propylene glycol
Study NCT04090801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical minoxidil 5% in pure ethanol alone
Description: The treatment will be continued twice daily.for six months with regular visits at 3 months intervals.
Study NCT04090801 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Ethanol)
Description: The treatment will be continued twice daily.for six months with regular visits at 3 months intervals.
Study NCT02453204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting
Study NCT02813694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: antibacterial agent
Study NCT02453204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standing
Study NCT02725723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therm-AppTM TH, thermographic camera
Study NCT02725723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epidural injection
Study NCT03522870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flash glucose monitoring system
Description: Using flash glucose monitoring system continuously on Week 2-14 and Week 14-26
Study NCT03522870 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SMBG
Description: Performing SMBG at least three times/day on Week 2-14 and Week 14-26